(-0.04%) 5 243.25 points
(-0.01%) 39 557 points
(-0.11%) 18 276 points
(-0.01%) $79.11
(-0.80%) $2.36
(0.19%) $2 347.40
(0.34%) $28.54
(0.07%) $1 011.50
(0.06%) $0.927
(0.14%) $10.82
(0.19%) $0.798
(-0.22%) $91.39
Live Chart Being Loaded With Signals
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally...
Stats | |
---|---|
Today's Volume | 359 364 |
Average Volume | 2.20M |
Market Cap | 234.45B |
EPS | INR0 ( 2024-04-24 ) |
Next earnings date | ( INR0 ) 2024-07-25 |
Last Dividend | INR1.200 ( 2023-05-10 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 145.97 |
ATR14 | INR0.456 (0.10%) |
Volume Correlation
Laurus Labs Limited Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Laurus Labs Limited Correlation - Currency/Commodity
Laurus Labs Limited Financials
Annual | 2023 |
Revenue: | INR50.41B |
Gross Profit: | INR15.84B (31.42 %) |
EPS: | INR2.98 |
FY | 2023 |
Revenue: | INR50.41B |
Gross Profit: | INR15.84B (31.42 %) |
EPS: | INR2.98 |
FY | 2022 |
Revenue: | INR60.41B |
Gross Profit: | INR32.66B (54.07 %) |
EPS: | INR14.69 |
FY | 2022 |
Revenue: | INR48.89B |
Gross Profit: | INR26.40B (54.01 %) |
EPS: | INR15.42 |
Financial Reports:
No articles found.
Laurus Labs Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0.800 (N/A) |
INR0 (N/A) |
INR1.200 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.300 | 2017-07-06 |
Last Dividend | INR1.200 | 2023-05-10 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | INR7.40 | -- |
Avg. Dividend % Per Year | 0.35% | -- |
Score | 2.97 | -- |
Div. Sustainability Score | 8.03 | |
Div.Growth Potential Score | 3.32 | |
Div. Directional Score | 5.68 | -- |
Year | Amount | Yield |
---|---|---|
2017 | INR0 | 0.00% |
2018 | INR0.300 | 0.30% |
2019 | INR0.300 | 0.39% |
2020 | INR1.300 | 1.77% |
2021 | INR2.00 | 0.57% |
2022 | INR2.00 | 0.38% |
2023 | INR1.200 | 0.32% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RPPL.NS | Dividend Junior | 2023-08-24 | Annually | 6 | 0.31% | |
LICHSGFIN.NS | Dividend Junior | 2023-08-18 | Annually | 23 | 1.85% | |
GABRIEL.NS | Dividend Knight | 2023-08-07 | Semi-Annually | 20 | 0.71% | |
APOLLO.NS | Dividend Junior | 2023-09-22 | Annually | 7 | 0.79% | |
TECHNOE.NS | Dividend Junior | 2023-09-15 | Annually | 16 | 1.13% | |
OMINFRAL.NS | Dividend Junior | 2023-09-22 | Annually | 13 | 0.78% | |
INGERRAND.NS | Dividend Junior | 2023-07-17 | Annually | 23 | 1.40% | |
CONFIPET.NS | Dividend Junior | 2023-09-22 | Annually | 5 | 0.11% | |
SHANTIGEAR.NS | Dividend Junior | 2023-07-11 | Annually | 23 | 1.02% | |
MANALIPETC.NS | Dividend Junior | 2023-09-15 | Annually | 18 | 1.50% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0318 | 1.500 | 9.36 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0191 | 1.200 | 9.36 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0396 | 1.500 | -0.672 | -1.007 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.232 | 0.800 | 8.84 | 7.07 | [1 - 3] |
quickRatioTTM | 0.584 | 0.800 | -1.272 | -1.017 | [0.8 - 2.5] |
cashRatioTTM | 0.0455 | 1.500 | -0.858 | -1.287 | [0.2 - 2] |
debtRatioTTM | 0.300 | -1.500 | 5.00 | -7.50 | [0 - 0.6] |
interestCoverageTTM | 2.19 | 1.000 | -0.300 | -0.300 | [3 - 30] |
operatingCashFlowPerShareTTM | 10.46 | 2.00 | 6.51 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 10.46 | 2.00 | 4.77 | 9.54 | [0 - 20] |
debtEquityRatioTTM | 0.612 | -1.500 | 7.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.465 | 1.000 | 5.58 | 5.58 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0795 | 1.000 | -0.410 | -0.410 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.224 | 1.000 | 9.86 | 9.86 | [0.2 - 2] |
assetTurnoverTTM | 0.601 | 0.800 | 9.33 | 7.46 | [0.5 - 2] |
Total Score | 8.03 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 145.64 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0396 | 2.50 | -0.432 | -1.007 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 10.46 | 2.00 | 6.51 | 9.54 | [0 - 30] |
dividendYielPercentageTTM | 0.277 | 1.500 | 3.07 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 10.46 | 2.00 | 6.51 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -30.76 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.112 | 1.000 | 9.70 | 0 | [0.1 - 0.5] |
Total Score | 3.32 |
Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators